The IRF6 (Interferon Regulatory Factor 6) antibody is a crucial tool in studying the role of IRF6. a transcription factor belonging to the interferon regulatory factor family. IRF6 is primarily known for its essential role in embryonic development, particularly in craniofacial morphogenesis and epidermal differentiation. Mutations in the IRF6 gene are linked to human congenital disorders such as Van der Woude syndrome and popliteal pterygium syndrome, characterized by cleft lip/palate and skin abnormalities. Research using IRF6 antibodies has elucidated its involvement in regulating epithelial cell proliferation, differentiation, and tissue fusion processes during development. The antibody is widely employed in techniques like Western blotting, immunohistochemistry, and immunofluorescence to detect IRF6 expression patterns in tissues and cell lines. Studies also explore IRF6's interaction with signaling pathways, including TGF-β and FGF, and its role in maintaining epithelial barrier integrity. Additionally, IRF6 dysregulation has been implicated in cancer progression, making its antibody a valuable reagent for investigating oncogenic mechanisms. Commercial IRF6 antibodies are typically raised against specific epitopes, often targeting conserved regions (e.g., amino acids 100-200) to ensure cross-species reactivity. Proper validation ensures specificity for research applications in developmental biology, genetics, and clinical diagnostics.